Metronidazole and Indian kala-azar: results of a clinical trial.
作者信息
Mishra M, Thakur B D, Choudhary M
出版信息
Br Med J (Clin Res Ed). 1985 Dec 7;291(6509):1611. doi: 10.1136/bmj.291.6509.1611.
Abstract
摘要
相似文献
1
Metronidazole and Indian kala-azar: results of a clinical trial.甲硝唑与印度黑热病：一项临床试验的结果
Br Med J (Clin Res Ed). 1985 Dec 7;291(6509):1611. doi: 10.1136/bmj.291.6509.1611.
2
Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.印度比哈尔邦内脏利什曼病流行地区的黑热病后皮肤利什曼病。
Trop Med Int Health. 2012 Nov;17(11):1345-8. doi: 10.1111/j.1365-3156.2012.03067.x. Epub 2012 Aug 12.
3
Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.用于治疗黑热病（内脏利什曼病）的口服有效药物：聚焦于米替福新和硝喹。
J Assoc Physicians India. 2003 Jul;51:686-90.
4
Visceral leishmaniasis (kala-azar) complicating acute leukaemia.内脏利什曼病（黑热病）并发急性白血病。
J Infect. 1983 Nov;7(3):272-4. doi: 10.1016/s0163-4453(83)97304-8.
5
6
A combination of sulphadiazine, trimethoprim and metronidazole or tinidazole in kala-azar.
J Assoc Physicians India. 1994 Jul;42(7):535-6.
7
Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit.印度内脏利什曼病的非侵入性管理：黑热病转诊单位K39抗原试纸条检测诊断的临床应用
Clin Infect Dis. 2002 Sep 1;35(5):581-6. doi: 10.1086/342057. Epub 2002 Jul 31.
8
Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report.巴西一名患者的皮肤利什曼病：病例报告
Rev Soc Bras Med Trop. 2018 Jan-Feb;51(1):105-107. doi: 10.1590/0037-8682-0487-2016.
9
Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.两性霉素B脂质体治疗内脏利什曼病后发生的黑热病后皮肤利什曼病：对印度消除计划的一个潜在挑战
J Postgrad Med. 2013 Jul-Sep;59(3):226-8. doi: 10.4103/0022-3859.118046.
10
Treatment of leishmaniasis with miltefosine: 2008 status.用米替福新治疗利什曼病：2008年现状。
Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1209-16. doi: 10.1517/17425255.4.9.1209.
引用本文的文献
1
Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease.代谢网络分析预测了美国食品药品监督管理局批准的针对一种被忽视热带病病原体的药物的疗效。
BMC Syst Biol. 2012 Apr 27;6:27. doi: 10.1186/1752-0509-6-27.
2
Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum.婴儿利什曼原虫引起的内脏利什曼病二线口服治疗的实验评估
Antimicrob Agents Chemother. 1999 Jan;43(1):172-4. doi: 10.1128/AAC.43.1.172.
3
Chemotherapy of leishmaniasis in India.印度利什曼病的化学疗法。
Indian J Pediatr. 1987 Jan-Feb;54(1):7-10. doi: 10.1007/BF02751226.
4
Co-trimoxazole for visceral leishmaniasis.复方新诺明用于治疗内脏利什曼病。
Infection. 1990 Jan-Feb;18(1):40. doi: 10.1007/BF01644182.
本文引用的文献
1
Inefficacy of metronidazole in experimental infections of Leishmania donovani, L. mexicana, and Trypanosoma brucei brucei.甲硝唑对杜氏利什曼原虫、墨西哥利什曼原虫及布氏布氏锥虫实验性感染无效。
Am J Trop Med Hyg. 1983 May;32(3):485-96. doi: 10.4269/ajtmh.1983.32.485.
2
Co-trimoxazole for leishmaniasis-or metronidazole?用于治疗利什曼病的复方新诺明——还是甲硝唑？
Lancet. 1981 Mar 21;1(8221):669. doi: 10.1016/s0140-6736(81)91590-7.
3
Co-trimoxazole for systemic leishmaniasis.复方新诺明治疗系统性利什曼病
Lancet. 1981 Feb 7;1(8215):323-4. doi: 10.1016/s0140-6736(81)91929-2.
4
An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani.一种用于测定化合物对杜氏利什曼原虫细胞内无鞭毛体形式活性的体外系统。
J Antimicrob Chemother. 1984 Nov;14(5):463-75. doi: 10.1093/jac/14.5.463.
Zotero 插件